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MinireviewNarcolepsy: A Neurodegenerative
Disease of the Hypocretin System?
Narcoleptics may also have hypnogogic hallucinations,
a complex state most likely to occur at the transition
between wake and sleep. Sleep problems are not re-
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stricted to the daytime; at night, narcoleptics often show333 Cedar Street
disturbed sleep patterns and may wake several times.New Haven, Connecticut 06520
The potential importance of hypocretin neurons in
preventing narcolepsy was first suggested by the finding
that narcoleptic dogs have mutations in one of the hypo-In the 21⁄2 years since hypocretin (also called orexin) was
cretin receptors, the hypocretin receptor 2 (orexin 2 re-first described (de Lecea et al., 1998; Sakurai et al.,
ceptor) (Lin et al., 1999). Although different mutations1998), more than 120 papers on the peptide have already
were found in each of two narcoleptic breeds of dogs,been published. A pair of current contributions to this
Dobermans and Labradors, in each breed the mutationrapidly expanding literature adds a new dimension to
was localized to the hypocretin receptor 2, rendering itour understanding of this new peptide neurotransmitter/
nonfunctional. Detection of this mutation culminated aneuromodulator. Although additional confirming work is
10 year search for a defective gene using positionalrequired, these new findings suggest that narcolepsy,
cloning. Parallel studies in hypocretin knockout micea condition characterized by serious sleep disturbances,
revealed a similar narcoleptic phenotype (Chemelli etmay be due to selective neurodegeneration of the hypo-
al., 1999), indicating that loss of either the peptide orthalamic hypocretin system. This would raise a disease
one of the two peptide receptors results in narcolepsy.that not too long ago could find itself on the couch of
These findings became even more exciting and relevantpsychoanalysis onto the stage of the more common
when hypocretin was found in the cerebrospinal fluid ofneurodegenerative diseases.
eight normal humans but could not be detected in sevenThe hypocretins are two peptides, hypocretin 1
of nine narcoleptics (Nishino et al., 2000).(orexin-A) and hypocretin 2 (orexin-B), generated from
Absence of Hypocretin Neuronsa single preprohypocretin and synthesized by a small
in Narcoleptic Brainnumber of neurons restricted to the lateral hypothala-
New data based on immunocytochemistry and in situmus and perifornical area (de Lecea et al., 1998; Sakurai
hybridization indicate that there is a substantially de-et al., 1998). In contrast, hypocretin axons are found
creased number of neurons producing hypocretin in thethroughout the CNS, with innervation of the hypothala-
hypothalamus of human narcoleptics (Peyron et al.,mus, locus coeruleus, raphe, midline thalamus, all levels
2000; Thannickal et al., 2000 [this issue of Neuron]).of spinal cord, sympathetic and parasympathetic cen-
Thannickal et al. show that the number of hypocretinters, and many other brain regions (Peyron et al., 1998;
immunoreactive neurons is decreased by about 90% invan den Pol, 1999). Two G protein–coupled receptors
four narcoleptic human brains. In parallel, Peyron et al.that respond to the hypocretins have been identified
show an absence of hypocretin mRNA from the hypo-(Sakurai et al., 1998). In parallel to the wide distribution of
thalamus, and the loss of hypocretin 1 and 2 peptides
axons, the two hypocretin receptors show a widespread
from extrahypothalamic hypocretin target regions of six
and heterogeneous pattern of expression throughout
narcoleptic brains. Although each study is based on a
the CNS (Trivedi et al., 1998). Hypocretin raises synaptic relatively small number of narcoleptic brain specimens,
activity in neurons of the hypothalamus (de Lecea et al., and each lab had only a few brain regions available, the
1998) and locus coeruleus (Hagan et al., 1999; Horvath combined brain number of both studies is ten, with six
et al., 1999). Hypocretin can act on postsynaptic recep- total hypothalami, although a possibility exists that one
tors to increase cytosolic calcium and can act at presyn- or two brains might have been shared by both groups.
aptic receptors on axon terminals to enhance release Both studies of narcoleptic brains report no decreased
of glutamate and GABA (van den Pol et al., 1998). The number of neurons containing melanin-concentrating
fact that hypocretin can enhance activity of either excit- hormone, a neuroactive peptide found in cells in the
atory or inhibitory neurons suggests that the peptide same general perifornical hypothalamic region where
could ultimately increase or decrease the activity of in- hypocretin neurons normally exist. This finding suggests
nervated brain circuits. a very selective absence of hypocretin neurons, rather
Dysfunction of Hypocretin System than a general loss of neurons from the hypothalamus.
Causes Narcolepsy The absence of hypocretin neurons could be due to a
Narcolepsy is a sleep disorder characterized by exces- number of factors, including degeneration of hypocretin
sive daytime sleepiness and unusual patterns of REM neurons, failure of hypocretin neurons to develop, a re-
sleep. Narcolepsy is often associated with cataplexy, a duced synthesis or release of the peptide, or some muta-
sudden loss of muscle tone evoked by strong emotion. tion in the DNA sequence coding for hypocretin. Sev-
During attacks of cataplexy that last a few seconds or eral lines of evidence support the hypothesis that
minutes, narcoleptics are conscious of their environ- hypocretin neurons may degenerate in narcoleptics.
ment but unable to move. This condition appears to be Thannickal et al. find about 10% of the normal number
related to muscle atonia that occurs during REM sleep. of hypocretin neurons in narcoleptics, suggesting that
the peptide was at least synthesized by a small propor-
tion of neurons, arguing against a total absence of hypo-* E-mail: anthony.vandenpol@yale.edu
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cretin neurons from birth. The detection of an increased cators of neuropathology including HLA-DR microglial
labeling, tumor necrosis factor in situ hybridization, thio-immunostaining of astrocytes in the hypocretin area of
the brain of narcoleptics also argues in favor of some nin, and crystal violet staining and reported no local
pathology in narcoleptics. Unlike Thannickal, Peyron didtype of postnatal degeneration. That narcolepsy is due
to postnatal neuron loss is consistent also with the wide not find enhanced GFAP staining. Together, the data
imply that although cells were lost at an earlier timerange of ages at which the disease generally is first
detected, usually in the middle teenage years. Most nar- point, suggested by the GFAP staining of some but not
all of the brains, no continuing state of degenerationcoleptics appear to have regular sleep–wake cycles in
their earlier lives, suggesting that the hypocretin system or immune response is found in narcoleptic brains. An
inherent complication in these studies is that the brainsmay be normal for many years prior to the development
of narcolepsy. That the absence of releasable hypocretin were obtained many years or decades after the disease
was detected, at a period when a local immune responsecan precipitate narcolepsy at very early ages is sug-
gested by the detection of narcolepsy in a 2-year-old to dying cells would have been obscured by the passage
of time. Differences in the two studies could be duechild (cataplexy found at 6 months of age) with a mutated
signal sequence (Peyron et al., 2000). In this patient, a to small sample sizes, different patient populations, or
different means (frozen or fixed) of tissue preservation.defect in the signal peptide sequence of hypocretin was
found, based on a G to T transversion in the DNA se- Earlier reports (Tafti et al., 1996; Siegel et al., 1999)
suggested that narcoleptic dogs (lacking the hypocretinquence, and a resultant arginine substituted for leu-
cine. In this case, hypocretin appeared to be synthe- receptor 2, but with normal hypocretin levels) show
pathological signs of neurodegeneration and microglialsized, but rather than being transported to secretory
vesicles for subsequent release, it instead accumulated influxes in nonhypothalamic brain regions. These canine
observations indicate either that activation of the hypo-in branching tubular bodies that were identified as
smooth endoplasmic reticulum by morphological over- cretin receptor 2 may be important in sustaining neu-
ronal survival or that the reports of neuropathology inlap with syntaxin-17. With this one exception, examina-
tion of the hypocretin gene from a number of narcoleptic the canine narcoleptic brains are not directly related to
narcolepsy and the hypocretin system.patients failed to detect a mutation associated with the
disease. A central question remains: if hypocretin cells are lost
postnatally, what might cause the specific disappear-Although the most parsimonious explanation of the
combined data is that hypocretin cells degenerate, dy- ance of these cells? One clue comes from the associa-
tion of narcolepsy in over 90% of patients with particularing hypocretin cells have not been identified, and the
less likely possibility that the neurons do not die, but alleles coding for class II human leucocyte antigens,
HLA DQB1*0602 and HLA-DR2, leading to the sugges-rather cease making hypocretin, remains. These ques-
tions may be addressed by future longitudinal experi- tion that the loss of hypocretin cells might be due to
an autoimmune condition (Honda, 1988; Mignot et al.,ments in humans showing that hypocretin is present in
CSF prior to the manifestation of narcoleptic symptoms, 1997). HLA class II molecules are expressed on the
surfaces of macrophages, dendritic, and B cells thatbut then is lost when symptoms appear. These experi-
ments are complicated by the difficulty in predicting present antigens to CD4-positive T cells. HLA-related
autoimmune disease could result in a cell- or antibody-who will become narcoleptic. Additional examination of
postmortem narcoleptic brain tissue obtained closer to mediated immune attack on restricted populations of
cells. Many normal humans (30%) have the same haplo-the time of disease onset, potentially examining inde-
pendent molecular markers of the hypocretin neurons, type, yet show no evidence of narcolepsy, indicating
that these alleles do not cause the disease but maywould also aid our understanding; these may be difficult
to obtain given the long life expectancy of narcoleptics. increase the sensitivity to other factors. The incidence
of the disease in first-order family members of a narco-Whereas degeneration of the hypocretin neurons may
account for narcolepsy, other less likely possibilities leptic is 1%–2%. Furthermore, the concordance rate
among monozygotic twins is not high (about 25%). To-have not been excluded. Even in the absence of a spe-
cific mutation in the hypocretin gene, other factors that gether, this suggests there may be some environmental
factor (toxin, chemical, virus, etc.) that might initiate anmight influence hypocretin synthesis and detection in-
clude mutations in specific transcription factors re- autoimmune imbalance.
One can only speculate at this point what might bequired for hypocretin transcription or alterations in pro-
teins required for proper splicing of the hypocretin RNA the precipitating factor in narcolepsy. One possibility
may be related to an infectious agent. An infectiousor its stability. Along these lines, a cause of Rett syn-
drome, a progressive neurodevelopmental disorder, is agent could target hypocretin neurons directly or could
alter the delicate balance between different classes ofthe mutation of a gene called methyl CpG binding protein
2 (MeCP2). Its protein product is required for successful T and B cells of the immune system by stimulating or
depressing specific cell types. Such an imbalance mightinitiation of transcription of other downstream genes,
and it is the absence of these gene products that is lead to the destruction of hypocretin cells due to a par-
ticular antigenic determinant on the neuronal surface.thought to lead to symptoms of the disorder.
The two studies differ in the detection of local hypo- Molecular mimicry could play a role, whereby an infec-
tious agent may express some antigenic determinantthalamic neuropathology. Based on increased immuno-
staining for glial fibrillary acidic protein (GFAP), Than- that is similar to one expressed by a specific cell. An
immune response to the foreign molecule results in annickal et al. suggest gliosis is found selectively in the
hypothalamus, but not in the thalamus of narcoleptic autoimmune response against the intrinsic cell sharing
that antigen. If hypocretin cells degenerate from an auto-brains. Peyron et al. studied a number of potential indi-
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immune response, it is possible that other neuronal sys- half a million people in the early part of the 20th century,
the disease has been rare for a number of years.tems that express a similar surface molecule may also
Hypocretin and Hypothalamic Functionbe targeted. At this point, there are no substantive data
Hypocretin initially generated interest because of its lo-giving direct support for an autoimmune attack on hypo-
cation in an area of the hypothalamus that plays a rolecretin neurons in narcoleptics.
in energy homeostasis and because of its putative roleNeurodegenerative Disease
in evoking feeding (Sakurai et al., 1998), generating anIf caused by degeneration of the hypocretin system,
alternate name for the peptide, orexin. Modest successnarcolepsy enters the fold of neurodegenerative dis-
in evoking feeding with intracerebral injections of hypo-eases that includes Parkinson’s (loss of nigral dopamine
cretin 1 or 2 has been reported by some (see Kilduffneurons), Huntington’s (loss of striatal neurons), Alzhei-
and Peyron, 2000). Human narcoleptics, rather than be-mer’s (widespread loss of neurons), amyotropic lateral
ing thin, tend to maintain a heavier body weight thansclerosis (motor neuron loss and demyelination), and a
controls (Honda, 1988), the opposite of what would benumber of other less frequently occurring diseases. As
expected from the loss of an orexigenic peptide.narcolepsy is found in about 1 of 2000 humans, a verifi-
Whether this weight gain is due directly to hypocretincation of the neurodegeneration hypothesis would es-
loss or to a secondary effect related to decreased activ-tablish narcolepsy as the third most prevalent type of
ity in narcoleptics is not clear. Although the role of hypo-neurodegenerative disease, behind Alzheimer’s (the
cretin in the regulation of body weight remains to bemost common) and Parkinson’s (which affects about 1
determined, hypocretin neurons do respond to a numberin 1000 humans), but more prevalent than Huntington’s
of metabolic signals, including insulin, glucose, and lep-or amyotropic lateral sclerosis (each about 1 in 5000).
tin, that reflect the state of energy resources. This sensi-It may be instructive to compare narcolepsy with com-
tivity may reflect a metabolically modulated arousal sys-mon neurodegenerative diseases. Most of these dis-
tem. For instance, in conditions of caloric deprivation,eases, including Parkinson’s, Huntington’s, and Alzhei-
it might be better to search for food, rather than sleep.mer’s, generally strike late in life, often in the 50s or
Given the focus of the narcolepsy literature on otherlater. In contrast, narcolepsy generally begins in the teen
brain regions such as the pons and medulla in recentyears. Parkinson’s patients can lose up to 80% of their
decades, the hypothalamus would not have been thedopamine cells before the more substantial motor dys-
first guess as the neuronal site responsible for narco-function is apparent, and dopamine cells may be lost
lepsy, although several decades earlier the hypothala-for years prior to symptomatic problems. Similar to Par-
mic region had been suggested as a probable brainkinson’s disease, hypocretin neurons may begin to die
locus regulating sleep and narcolepsy (von Economo,long before the first symptoms of narcolepsy are de-
1930; Nauta, 1946). Narcolepsy includes a number oftected. Nigral dopamine neurons from Parkinson brains
symptoms not generally associated with hypothalamicshow characteristic Lewy bodies, brains from Alzhei-
function. For instance, hypnogogic hallucinations aremer’s show plaques and tangles, Huntington brains
not uncommon in narcolepsy—these are often of anshow neuron loss and gliosis, and amyotropic lateral
unpleasant or negative nature; hallucinations have gen-sclerosis patients show motor neuron loss and demy-
erally been considered the domain of higher brain re-elination. Whether hypocretin neurons show some neu-
gions, particularly the cortex. In contrast to the negativ-ropathological sign of dysfunction prior to loss remains
ity of the hallucinations, the sudden loss of skeletalto be determined. Patients with the other neurodegener-
muscle tone in cataplexy is generally precipitated byative diseases generally deteriorate over years, in large
strong emotional situations of a positive nature, andpart due to a continued loss of neurons. Although pa-
less frequently by emotional situations with a negativetients with narcolepsy do not recover, they generally do
overtone (Honda, 1988). Regulation of muscle tone hasnot show continued decline, and unlike most of the other
not generally been considered a function of the hypo-
diseases, narcolepsy is not fatal. Similar to narcolepsy,
thalamus, yet with the absence of hypothalamic hypo-
the specific causes of Parkinson’s, amyotropic lateral
cretin, transient paralysis occurs during cataplexy. Thus,
sclerosis, and Alzheimer’s remain to be determined. Al- the absence of hypocretin neurons reveals new dimen-
though we do not know the cause of most cases of the sions to hypothalamic function.
disease, Parkinson’s syndrome can be precipitated by Hypocretin Agonists and Antagonists
both chemical toxins and viral agents. MPTP can de- If the absence of hypocretin leads to narcolepsy, can the
stroy dopamine neurons of the nigra resulting in Parkin- symptoms of narcolepsy be alleviated by hypocretin?
son’s syndrome. Parkinson symptoms have also been Possibly. However, global elevation of hypocretin may
found at long intervals after illness due to von Eco- not stimulate the receptors selectively as would release
nomo’s disease, probably resulting from a neurotropic of the peptide at specific synaptic sites. In rodents, intra-
virus. The other name for this disease is encephalitis cerebral injections of hypocretin do increase arousal
lethargica, related to the extended sleepiness caused and alter sleep patterns (Hagan et al., 1999). The hypo-
by the disease. Degeneration in both the nigral and hy- cretins have poor permeability across the blood brain
pothalamic areas has been reported in postmortem ex- barrier; if a hypocretin agonist can be designed that
aminations. It would be interesting to determine if a would survive the intestinal tract and have enhanced
virally initiated degeneration had occurred to the hypo- permeability into the brain, it may reduce the symptoms
thalamic hypocretin system potentially contributing to of narcolepsy. The symptoms of narcolepsy are cur-
sleep problems including narcolepsy found in some pa- rently treated with amphetamines or related com-
tients as an aftermath of the disease. Although an epi- pounds. These can have significant negative side ef-
fects, including habituation, dependence, heighteneddemic of this encephalitis resulted in the death of up to
Neuron
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Tafti, M., Nishino, S., Aldrich, M.S., Liao, W., Dement, W.C., andanxiety, and weight loss. It will be interesting to see
Mignot, E. (1996). J. Neurosci. 16, 4588–4595.what actions hypocretin agonists might have on human
Thannickal, R., Moore, R.Y., Nienhuis, R., Ramanathan, L., Gulyani,behavior and mental function. Given the role hypocretin
S., Aldrich, M., Cornford, M., and Siegel, J.M. (2000). Neuron 27,appears to play in arousal, hypocretin agonists might
this issue, 469–474.
serve as a safer substitute for amphetamines in a wide
Trivedi, P., Yu, H., MacNeil, D.J., van der Ploeg, L.H., and Guan,
range of situations where amphetamines are now em- X.M. (1998). FEBS Lett. 438, 71–75.
ployed. Serotonin and norepinephrine systems are key
van den Pol, A.N. (1999). J. Neurosci. 19, 3171–3182.
targets for many drugs used to treat mental illness, in-
van den Pol, A.N., Gao, X.B., Obrietan, K., Kilduff, T., and Belousov,
cluding depression, anxiety, bipolar, and attention defi- A. (1998). J. Neurosci. 18, 7962–7971.
cit hyperactivity disorders; given the strong hypocretin von Economo, C. (1930). J. Nerv. Ment. Dis. 71, 249–259.
innervation of the raphe and locus coeruleus, a primary
origin of these systems, hypocretin agonists may ame-
liorate or exacerbate these conditions. A number of in-
triguing questions emerge. Do sleep problems in aged
humans relate to ongoing loss of hypocretin neurons?
Does an exaggerated axonal release of hypocretin or
sensitized hypocretin receptors underlie insomnia or
other problems relating to sleep difficulty, and could
hypocretin antagonists be used as an effective treat-
ment? Would hypocretin agonists enhance alertness or
facilitate concentration?
The hypocretin story to date is an excellent example
of the importance of basic cellular, molecular, and whole
animal studies that can serve as a critical substrate for
understanding the cause of human brain disease. The
rapidity of the hypocretin story is a credit to the National
Institute of Health that funded much of the basic and
clinically related research leading to the discovery that
hypocretin absence is a primary cause of narcolepsy.
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